Urgent

Warm autoimmune haemolytic anaemia (warm AIHA; IgG-mediated autoimmune haemolysis)

Haemolytic anaemia · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

IgG autoantibodies (optimal at 37 C) coat red cells -> extravascular splenic destruction. Primary or secondary (lymphoma/CLL, SLE, drugs, infection). Presents with rapid anaemia, jaundice, splenomegaly. Steroids are first-line. Transfuse for life-threatening anaemia despite cross-match difficulty - do not withhold.

Red flags

  • Rapidly falling Hb with angina, dyspnoea, altered mentation (critical anaemia)
  • Haemoglobinuria / acute kidney injury
  • Features of underlying lymphoma/CLL (lymphadenopathy, B symptoms)
  • Concurrent thrombocytopenia (Evans syndrome) with bleeding
  • Signs suggesting TTP (fever, neuro, renal, schistocytes) - different, urgent pathway

Assessment

Differential diagnosis

  • Cold agglutinin disease / paroxysmal cold haemoglobinuria (cold AIHA)
  • Hereditary haemolysis (G6PD, spherocytosis, sickle)
  • Microangiopathic haemolysis (TTP/HUS/DIC) - needs blood film
  • Drug-induced immune haemolysis
  • Evans syndrome (AIHA + ITP)
  • Hypersplenism, mechanical valve haemolysis

Investigations

  • Direct antiglobulin test (DAT/Coombs): IgG +/- C3d positive (warm pattern)
  • FBC + reticulocytes (raised), blood film (spherocytes, polychromasia, agglutination)
  • Haemolysis screen: unconjugated bilirubin up, LDH up, haptoglobin down, urinary urobilinogen/haemoglobinuria
  • Group & screen - warn lab (autoantibody complicates cross-match; need extended phenotype)
  • Screen for secondary cause: SLE serology, CT/LDH/paraprotein for lymphoproliferative, viral serology, drug history
  • G6PD if differential unclear

Management

  • Confirm haemolysis + warm DAT pattern; exclude microangiopathy on film (do NOT miss TTP)
  • Start corticosteroids - first-line for warm AIHA
  • Folic acid supplementation (ongoing haemolysis consumes folate)
  • Transfuse if symptomatic/life-threatening anaemia - give least-incompatible / best-match units, do not delay for perfect cross-match; transfuse slowly with monitoring
  • Identify and treat/stop secondary cause (drug, underlying lymphoproliferative or autoimmune disease)
  • Add rituximab early if severe or steroid-refractory; consider IVIG as temporising measure
  • VTE prophylaxis - active haemolysis is prothrombotic
  • If refractory: splenectomy (ensure vaccination) or other immunosuppression per haematology

Drugs & doses

Prednisolone 1 mg/kg PO once daily (typical 60-100 mg) until Hb recovers, then slow taper over weeks-months [verify local dose]
Methylprednisolone 100-250 mg IV daily for severe/fulminant haemolysis [verify local dose]
Folic acid 5 mg PO once daily
Rituximab 375 mg/m2 IV weekly x4 (or 1000 mg x2) for steroid-refractory/relapsing disease [verify local dose]
IVIG 0.4 g/kg/day IV x5 days - temporising only, less effective than in ITP [verify local dose]
Transfuse packed red cells - least incompatible units, warmed, slow with close monitoring

Disposition

Admit under medicine/haematology for significant symptomatic anaemia. Critical anaemia or cardiorespiratory compromise -> HDU. Haematology-led immunosuppression and workup for secondary cause.

Complications & pitfalls

  • High-output cardiac failure from severe anaemia
  • Venous/arterial thromboembolism
  • Steroid complications, infection on immunosuppression
  • Relapse / chronic transfusion dependence
  • Post-splenectomy sepsis

Exam pearls

  • Transfusion is NOT contraindicated - 'least incompatible' blood saves lives; liaise with transfusion lab early
  • Always look for a secondary cause - new warm AIHA in an older patient may be the first sign of CLL/lymphoma
  • Spherocytes on film + positive DAT distinguishes AIHA from hereditary spherocytosis (DAT negative)
  • Folate replacement often forgotten in brisk haemolysis
  • Rituximab now used early as steroid-sparing agent

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.